Recce Pharmaceuticals (ASX:RCE): A multi-billion-dollar sepsis solution?, page-11

December burns update stated "The study is on-going, with target patient enrolment/treatment expected early 2022,allowing full data-set reporting to follow."

seems to indicate they expected all 30 participants to be enrolled/treated early 2022? It is now may and that update from gitmo seemed to indicate they are a long way from target. I would think early 22 would be before mid year?

It is frustrating as it just plays into the hands of shorters again, I think Rce unfortunately have very little say in the burns trial since it seems it was proposed and funded by others? It is a shame as after the initial results I had thought burns or any other surface treatment might become a fast track way to approval of a product and income generation. Now it seems burns hospital are only using it as last resort on burns that do not respond to standard care? I wonder if they had a number of acute/ chronic untreatable cases initially that prompted the trial and all were treated successfully, so now no new patients until new chronic cases appear?